Litcius/Paper detail

Dose-related effects of ketamine for antidepressant-resistant symptoms of posttraumatic stress disorder in veterans and active duty military: a double-blind, randomized, placebo-controlled multi-center clinical trial

Chadi G. Abdallah, John D. Roache, Ralitza Gueorguieva, Lynnette A. Averill, Stacey Young‐McCaughan, Paulo Shiroma, Prerana Purohit, Antoinette Brundige, William Murff, Kyung-Heup Ahn, Mohamed Sherif, Eric J. Baltutis, Mohini Ranganathan, Deepak Cyril D’Souza, Brenda Martini, Steven M. Southwick, Ismene L. Petrakis, Rebecca R. Burson, Kevin B. Guthmiller, Argelio L. López-Roca, Karl A. Lautenschlager, John P. McCallin, Matthew B. Hoch, Alexandar Timchenko, Sergio E. Souza, Charles E. Bryant, Jim Mintz, Brett T. Litz, Douglas E. Williamson, Terence M. Keane, Alan L. Peterson, John H. Krystal

2022Neuropsychopharmacology108 citationsDOIOpen Access PDF

Topics & Concepts

KetaminePlaceboRandomized controlled trialTolerabilityMedicineDissociativeDiscontinuationAnesthesiaAntidepressantHamilton Rating Scale for DepressionClinical trialMajor depressive disorderPsychiatryPsychologyAdverse effectInternal medicineAnxietyCognitionAlternative medicinePathologyTreatment of Major DepressionAnesthesia and Neurotoxicity ResearchTryptophan and brain disorders
Dose-related effects of ketamine for antidepressant-resistant symptoms of posttraumatic stress disorder in veterans and active duty military: a double-blind, randomized, placebo-controlled multi-center clinical trial | Litcius